

Attorney Docket No.: RTS-0253
Inventors: Susan M. Freier
Serial No.: 09/975,123
Filing Date: October 9, 2001
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): An antisense compound oligonucleotide 8 to 50 nucleobases in length targeted to nucleobases 580 through 629 or nucleobases 676 through 728 of a coding region, nucleobases 996 through 1205 or nucleobases 1579 through 1598 of a 3' untranslated region of a nucleic acid molecule (SEQ ID NO: 3) encoding insulin-like growth factor binding protein 5, nucleobases 11 through 30 or nucleobases 584 through 603 of a nucleic acid molecule (SEQ ID NO: 10) encoding insulin-like growth factor binding protein 5, nucleobases 4214 through 4233 of an intron region or nucleobases 16817 through 16836 of an intron/exon junction region of a nucleic acid molecule (SEQ ID NO: 11) encoding insulin-like growth factor binding protein 5, or nucleobases 197 through 216 of a 3' untranslated region of a nucleic acid molecule (SEQ ID NO: 12) encoding insulin-like growth factor binding protein 5, wherein said ~~compound~~ oligonucleotide specifically hybridizes with one of said regions and inhibits the expression of insulin-like growth factor binding protein 5.

Attorney Docket No.: RTS-0253
Inventors: Susan M. Freier
Serial No.: 09/975,123
Filing Date: October 9, 2001
Page 3

Claim 2 (canceled).

Claim 3 (re-presented - formerly dependent claim 2): The antisense compound oligonucleotide of ~~claim 2~~ claim 1 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 15, 18, 23, 24, 26, 27, 28, 29, 30, 33, 34, 35, 36, 38, 39, 40, 41, 42 or 43.

Claim 4 (re-presented - formerly dependent claim 2): The antisense compound oligonucleotide of ~~claim 2~~ claim 1 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (currently amended): The antisense compound oligonucleotide of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (re-presented - formerly dependent claim 2): The antisense compound oligonucleotide of ~~claim 2~~ claim 1 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (currently amended): The antisense compound oligonucleotide of claim 6 wherein the modified sugar moiety is a 2'-o-methoxyethyl sugar moiety.

Attorney Docket No.: RTS-0253
Inventors: Susan M. Freier
Serial No.: 09/975,123
Filing Date: October 9, 2001
Page 4

Claim 8 (re-presented - formerly dependent claim 2): The antisense ~~compound~~ oligonucleotide of ~~claim 2~~ claim 1 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (currently amended): The antisense ~~compound~~ oligonucleotide of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (re-presented - formerly dependent claim 2): The antisense ~~compound~~ oligonucleotide of ~~claim 2~~ claim 1 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (previously canceled).

Claim 12 (currently amended): A composition comprising the antisense ~~compound~~ oligonucleotide of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (canceled).

Claim 15 (currently amended): A method of inhibiting the expression of insulin-like growth factor binding protein 5 in cells or tissues *in vitro* comprising contacting said cells or tissues *in vitro* with the antisense ~~compound~~ oligonucleotide of claim 1 so

Attorney Docket No.: RTS-0253
Inventors: Susan M. Freier
Serial No.: 09/975,123
Filing Date: October 9, 2001
Page 5

that expression of insulin-like growth factor binding protein 5 is inhibited.

Claims 16-20 (previously canceled)

Claim 21 (currently amended): An antisense compound
oligonucleotide consisting of SEQ ID NO: 14, 16, 17, 19, 21 or 25.